Effect of Highly Active Antiretroviral Therapy on the Incidence and Clinical Manifestations of Visceral Leishmaniasis in Human Immunodeficiency Virus-Infected Patients

Clinical Infectious Diseases

Volumn 37, Issue 7, 2003, Pages 973-977

  Fernandez Cotarelo M J ^a   Abellana Martinez J ^a   Guerra Vales, J M ^a   Martinez Sanchez P ^a   Rodrigo Gomez De La Barcena M ^a   Salto Fernandez E ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DRUG EFFECT; FEMALE; FEVER; HEPATOSPLENOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST PARASITE INTERACTION; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGAMMAGLOBULINEMIA; HYPOALBUMINEMIA; LEISHMANIA; MALE; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; WEIGHT REDUCTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED;

EID: 18844467292     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377607     Document Type: Article

References (20)

1. Alvar J, Cañavate C, Gutiérrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298-319.
2. Reus S, Sánchez R, Portilla J, et al. Visceral leishmaniasis: a comparative study of patients with and without HIV infection [in Spanish]. Enferm Infecc Microbiol Clin 1999; 17:515-20.
3. Pintado V, Martín-Rabadán P, Rivera ML, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: a comparative study. Medicine (Baltimore) 2001; 80:54-73.
4. Berhe N, Wolday D, Hailu A, et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 1999; 13:1921-5.
5. Jiménez-Expósito MJ, Alonso-Villaverde C, Sardá P, Masana L. Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy. AIDS 1999; 13:152-3.
6. De La Rosa R, Pineda JA, Delgado J, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 2002; 40:762-7.
7. Fernández-Rivera J, Macías J, García-García JA, Ramos AJ, Leal M, Pineda JA. Effect of highly active antiretroviral therapy on the clinical onset of AIDS defined by clinical episodes [in Spanish]. Med Clin (Barc) 2002; 118:686-8.
8. de la Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001; 32:633-5.
9. del Giudice P, Mary-Krause M, Pradier C, et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002; 186:1366-70.
10. López-Vélez R, Casado JL, Pintado V. Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clin Microbiol Infect 2001; 7:394-5.
11. Tumbarello M, Tacconelli E, Bertagnolio S, Cauda R. Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. AIDS 2000; 14:2948-9.
12. Tortajada C, Perez-Cuevas B, Moreno A, et al. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:364-6.
13. Rosenthal E, Tempesta S, Del Giudice P, et al. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS 2001; 15:1184-5.
14. Villanueva JL, Alarcón A, Bernabeu-Wittel M, et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2000; 19:798-801.
15. Casado JL, López-Vélez R, Pintado V, Quereda C, Antela A, Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001; 20:202-5.
16. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition of AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-119.
17. Pintado V, López-Vélez R. Visceral leishmaniasis associated with human immunodeficiency virus infection [in Spanish]. Enferm Infecc Microbiol Clin 2001; 19:353-7.
18. Pineda JA, Gallardo JA, Macías J, et al. Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency viras type 1-infected patients in southern Spain. J Clin Microbiol 1998; 36:2419-22.
19. Delgado Fernández M, García Ordóñez MA, Martos Pérez F, Reguera Iglesias JM, Jiménez Oñate F, Colmenero Castillo JD. Clinical and evolutional characteristics of visceral leishmaniasis in HIV infected patients [in Spanish]. An Med Interna (Madrid) 1997; 14:506-10.
20. + T-lymphocyte counts. AIDS 1998; 12:2147-53.